Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.

Cancer research - 15 Apr 2000

Ribas A, Butterfield L H, Hu B, Dissette V B, Meng W S, Koh A, Andrews K J, Lee M, Amar S N, Glaspy J A, McBride W H, Economou J S

Abstract excerpt

Genetic immunization with a single injection of dendritic cells (DCs) expressing a model melanoma antigen generates antigen-specific, MHC-restricted, protective immune responses. After initiating the immune response, additional vaccinations may increase the protection or conversely downregulate the immune response. Groups of mice were vaccinated several times with DCs transduced with the MART-1 gene, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fas Receptor

Share to Melanoma, Experimental

Share to T-Lymphocytes, Cytotoxic

Share to Th1 Cells

Share to Th2 Cells

Share to Vaccination

Source

Identifiers

PMID: 10786687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.PMID 10786687Read ↗

Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.Semantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway.Semantic proximity Read ↗

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injectionSemantic proximity Read ↗

New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Semantic proximity Read ↗

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.Semantic proximity Read ↗

Targeting dendritic cell signaling to regulate the response to immunization.Semantic proximity Read ↗

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph nodeSemantic proximity Read ↗

Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo.Semantic proximity Read ↗

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.Semantic proximity Read ↗

Protective antitumor activity through dendritic cell immunization is mediated by NK cell as well as CTL activation.Semantic proximity Read ↗

Cytotoxic effector T cells elicited by the killed tumor vaccine differ significantly from the effectors generated during active growth of a murine B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.